FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387095613> ?p ?o ?g. }

• W4387095613 abstract "Introduction Elevated transaminases and/or creatine phosphokinase can indicate underlying muscle disease. Therefore, this study aims to determine the frequency of Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD) in male children and Pompe disease (PD) in male and female children with isolated hypertransaminasemia. Methods This multi-center, prospective study enrolled patients aged 3–216 months with serum alanine transaminase (ALT) and/or aspartate transaminase (AST) levels &gt;2× the upper limit of normal (ULN) for ≥3 months. Patients with a known history of liver or muscle disease or physical examination findings suggestive of liver disease were excluded. Patients were screened for creatinine phosphokinase (CPK) levels, and molecular genetic tests for DMD/BMD in male patients and enzyme analysis for PD in male and female patients with elevated CPK levels were performed. Genetic analyses confirmed PD. Demographic, clinical, and laboratory characteristics of the patients were analyzed. Results Overall, 589 patients [66.8% male, mean age of 63.4 months (standard deviation: 60.5)] were included. In total, 251 patients (188 male and 63 female) had CPK levels above the ULN. Of the patients assessed, 47% (85/182) of male patients were diagnosed with DMD/BMD and 1% (3/228) of male and female patients were diagnosed with PD. The median ALT, AST, and CPK levels were statistically significantly higher, and the questioned neurological symptoms and previously unnoticed examination findings were more common in DMD/BMD patients than those without DMD/BMD or PD ( p &lt; 0.001). Discussion Questioning neurological symptoms, conducting a complete physical examination, and testing for CPK levels in patients with isolated hypertransaminasemia will prevent costly and time-consuming investigations for liver diseases and will lead to the diagnosis of occult neuromuscular diseases. Trial Registration Clinicaltrials.gov NCT04120168." @default.
• W4387095613 created "2023-09-28" @default.
• W4387095613 creator A5000491079 @default.
• W4387095613 creator A5010232871 @default.
• W4387095613 creator A5013607476 @default.
• W4387095613 creator A5027884361 @default.
• W4387095613 creator A5028794954 @default.
• W4387095613 creator A5033149838 @default.
• W4387095613 creator A5035253408 @default.
• W4387095613 creator A5050176918 @default.
• W4387095613 creator A5057638202 @default.
• W4387095613 creator A5065294505 @default.
• W4387095613 creator A5068106702 @default.
• W4387095613 creator A5075062077 @default.
• W4387095613 creator A5077240731 @default.
• W4387095613 creator A5078146383 @default.
• W4387095613 creator A5079076971 @default.
• W4387095613 creator A5079804465 @default.
• W4387095613 creator A5081370839 @default.
• W4387095613 creator A5086100134 @default.
• W4387095613 creator A5092952994 @default.
• W4387095613 date "2023-09-25" @default.
• W4387095613 modified "2023-10-13" @default.
• W4387095613 title "The frequency of Duchenne muscular dystrophy/Becker muscular dystrophy and Pompe disease in children with isolated transaminase elevation: results from the observational VICTORIA study" @default.
• W4387095613 cites W1462754900 @default.
• W4387095613 cites W1605796582 @default.
• W4387095613 cites W2036222646 @default.
• W4387095613 cites W2063752072 @default.
• W4387095613 cites W2092779189 @default.
• W4387095613 cites W2119439822 @default.
• W4387095613 cites W2124986207 @default.
• W4387095613 cites W2150418805 @default.
• W4387095613 cites W2302143479 @default.
• W4387095613 cites W2772982969 @default.
• W4387095613 cites W2784397775 @default.
• W4387095613 cites W2784992484 @default.
• W4387095613 cites W2965599913 @default.
• W4387095613 cites W3014924448 @default.
• W4387095613 cites W3033757480 @default.
• W4387095613 cites W4233842984 @default.
• W4387095613 cites W4289834426 @default.
• W4387095613 cites W4291512413 @default.
• W4387095613 cites W4360602378 @default.
• W4387095613 cites W93804728 @default.
• W4387095613 doi "https://doi.org/10.3389/fped.2023.1272177" @default.
• W4387095613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37818166" @default.
• W4387095613 hasPublicationYear "2023" @default.
• W4387095613 type Work @default.
• W4387095613 citedByCount "0" @default.
• W4387095613 crossrefType "journal-article" @default.
• W4387095613 hasAuthorship W4387095613A5000491079 @default.
• W4387095613 hasAuthorship W4387095613A5010232871 @default.
• W4387095613 hasAuthorship W4387095613A5013607476 @default.
• W4387095613 hasAuthorship W4387095613A5027884361 @default.
• W4387095613 hasAuthorship W4387095613A5028794954 @default.
• W4387095613 hasAuthorship W4387095613A5033149838 @default.
• W4387095613 hasAuthorship W4387095613A5035253408 @default.
• W4387095613 hasAuthorship W4387095613A5050176918 @default.
• W4387095613 hasAuthorship W4387095613A5057638202 @default.
• W4387095613 hasAuthorship W4387095613A5065294505 @default.
• W4387095613 hasAuthorship W4387095613A5068106702 @default.
• W4387095613 hasAuthorship W4387095613A5075062077 @default.
• W4387095613 hasAuthorship W4387095613A5077240731 @default.
• W4387095613 hasAuthorship W4387095613A5078146383 @default.
• W4387095613 hasAuthorship W4387095613A5079076971 @default.
• W4387095613 hasAuthorship W4387095613A5079804465 @default.
• W4387095613 hasAuthorship W4387095613A5081370839 @default.
• W4387095613 hasAuthorship W4387095613A5086100134 @default.
• W4387095613 hasAuthorship W4387095613A5092952994 @default.
• W4387095613 hasBestOaLocation W43870956131 @default.
• W4387095613 hasConcept C126322002 @default.
• W4387095613 hasConcept C160160445 @default.
• W4387095613 hasConcept C181199279 @default.
• W4387095613 hasConcept C185592680 @default.
• W4387095613 hasConcept C187212893 @default.
• W4387095613 hasConcept C2776877979 @default.
• W4387095613 hasConcept C2777404818 @default.
• W4387095613 hasConcept C2778606649 @default.
• W4387095613 hasConcept C2778943923 @default.
• W4387095613 hasConcept C2779030066 @default.
• W4387095613 hasConcept C2779134260 @default.
• W4387095613 hasConcept C2779679107 @default.
• W4387095613 hasConcept C2779969927 @default.
• W4387095613 hasConcept C2780567839 @default.
• W4387095613 hasConcept C36880943 @default.
• W4387095613 hasConcept C55493867 @default.
• W4387095613 hasConcept C71924100 @default.
• W4387095613 hasConcept C90924648 @default.
• W4387095613 hasConceptScore W4387095613C126322002 @default.
• W4387095613 hasConceptScore W4387095613C160160445 @default.
• W4387095613 hasConceptScore W4387095613C181199279 @default.
• W4387095613 hasConceptScore W4387095613C185592680 @default.
• W4387095613 hasConceptScore W4387095613C187212893 @default.
• W4387095613 hasConceptScore W4387095613C2776877979 @default.
• W4387095613 hasConceptScore W4387095613C2777404818 @default.
• W4387095613 hasConceptScore W4387095613C2778606649 @default.
• W4387095613 hasConceptScore W4387095613C2778943923 @default.
• W4387095613 hasConceptScore W4387095613C2779030066 @default.
• W4387095613 hasConceptScore W4387095613C2779134260 @default.
• W4387095613 hasConceptScore W4387095613C2779679107 @default.

• next